American Journal of Industrial Medicine · 1999 · 18 citations · 40 references
MedicineOncologyToxicologyEnvironmental ToxicologyMolecular OncologyRadiobiologyLung CancerMalignant NeoplasmsOccupational CarcinogenesisRadiation ToxicityLung Cancer EpidemiologyOccupational Cancer BiomarkersOccupational Cancer ExposuresOccupational Lung CancerP53 AbnormalityP53 MutationRadiation BiomarkersTumor Suppressor P53
BACKGROUND: The oncogene product EGF-receptor (EGF-R), the tumor suppressor gene product p53, and anti-p53 antibodies are detectable in serum of certain cancer patients. Increased levels of some of these products were reported in lung cancer patients after occupational asbestos exposure, after exposure to polycyclic aromatic hydrocarbons or vinyl chloride. This molecular epidemiological study investigated the use of serum EGF-R, p53-protein, and anti-p53 antibodies as biomarkers for detection of effects of radon and its decay products. METHODS: Serum EGF-R, p53-protein, and anti-53 antibodies were measured using ELISA in former uranium miners of SDAG Wismut without lung disease (n=106) and miners with Schneeberg lung cancer (n=22). They were compared with healthy subjects (n=23), patients with lung cancer not due to ionizing radiation (n=88), and patients with non-malignant lung or pleural diseases (n=50). RESULTS: No significantly elevated or decreased serum values for p53 protein, EGF-R, or anti-p53 antibodies could be found. There was no correlation of these with Working Level Months (WLM). CONCLUSIONS: p53 protein, EGF-R, or anti-p53 antibodies in serum are not useful as biomarkers for detection of lung cancer related to ionizing radiation (i.e., Schneeberg lung cancer).
40
Serum p53 antibodies as early markers of lung cancer
Richard Lubin, Gérard Zalcman, Laurence Bouchet et al. · Nature Medicine · 1995 · 330 citations
Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners
Kirsi Vähäkangas, Robert A. Metcalf, Judith A. Welsh et al. · The Lancet · 1992 · 321 citations